Verkazia reduced most symptoms of vernal keratoconjunctivitis (VKC) as early as month 11,2

Verkazia was tested against its cationic ophthalmic emulsion in clinical trials1

Image
background image
Image
background image mobile
1200ms
Image
Verkazia demonstrated substantial reductions in multiple symptoms
Image
Verkazia demonstrated substantial reductions in multiple symptoms

4 months of treatment with Verkazia led to complete remission of disease in this 8-year-old male patient3,4

Image
image mobile
Image
image

Individual results may vary.

Photographs courtesy of Andrea Leonardi, MD, PhD, Department of Neuroscience, Ophthalmology Unit, Orthoptic and Assistant in Ophthalmology School, University of Padua, Italy.

Verkazia delivered substantial reductions in itching scores as early as month 11 

Verkazia demonstrated consistent reductions in itching scores month over month1

57% mean reduction of itching score from baseline at month 41

Image
See reductions in itching scores from baseline over 4 months

57% mean reduction of itching score from baseline at month 41

Image
See reductions in itching scores from baseline over 4 months

Itching score at each visit was measured using a Visual Analogue Scale (0=no itch to 100=maximal itch).

Image
Verkazia effectively treats itching
Image
Verkazia effectively treats itching

Verkazia delivered substantial reductions in keratitis scores as early as month 11 

Verkazia demonstrated consistent reductions in keratitis scores month over month1

53% mean reduction from baseline in CFS scores at month 41

Image
See reduction in keratitis scores from baseline over 4 months

53% mean reduction from baseline in CFS scores at month 41

Image
See reduction in keratitis scores from baseline over 4 months

Corneal fluorescein staining (CFS) score was measured at each month using a 5-point scale (0=no stain, and 5=more stain).

Image
Verkazia effectively treats keratitis
Image
Verkazia effectively treats keratitis

Baseline characteristics in the pivotal trial2

Select a category

  • Verkazia
    4x/day
  • Verkazia
    2x/day
  • Cationic ophthalmic emulsion
  • Characteristic
  • Verkazia 4x/day
    (n=56)
  • Verkazia 2x/day
    (n=54)
  • Cationic ophthalmic emulsion 4x/day
    (n=58)
  • Age (yrs), mean (SD)
  • 9.1 (3.3)
  • 9.6 (3.4)
  • 8.9 (3.2)
  • Percent male
  • 78.6
  • 77.8
  • 79.3
  • Number of patients (%)*
  •  
  •  
  •  
  • VKC grade 3
  • 32 (57.1)
  • 32 (59.3)
  • 40 (69.0)
  • VKC grade 4
  • 24 (42.9)
  • 22 (40.7)
  • 18 (31.0)
  • Number of patients (%)
  •  
  •  
  •  
  • CFS score 4
  • 42 (75.0)
  • 49 (90.7)
  • 54 (93.1)
  • CFS score 5
  • 14 (25.0)
  • 5 (9.3)
  • 4 (6.9)

CFS=corneal fluorescein staining, SD=standard deviation, VKC=vernal keratoconjunctivitis.

*Graded by Bonini scale.

Scored by modified Oxford scale.

Image
background
1200ms
Image
Learn more about participants in the VEKTIS study
Image
Learn more about participants in the VEKTIS study

Verkazia delivered significant improvement in other common VKC signs and symptoms in the pivotal trial2,3

  • Image
    See results in photophobia

    Photophobia

  • Image
    See results in tearing

    Tearing

  • Image
    See results in mucous discharge

    Mucous discharge

Select a category

Select a category

  • Photophobia

  • Tearing

  • Mucous discharge

Reductions in photophobia scores from baseline as early as month 12,3

63% mean reduction from baseline in photophobia scores at month 42,3

Image
See reductions in photophobia scores vs baseline over 4 months
Image
See reductions in photophobia scores vs baseline over 4 months

Least squares mean difference based on linear mixed model for repeated measures with treatment, visit, proportion of time within VKC season, baseline, treatment by visit, and patient as covariates.
Each symptom score at each visit was measured using a Visual Analogue Scale (0=no experience of symptom to 100=maximal experience of symptom).

Image
Verkazia effectively treats photophobia

Reductions in tearing scores from baseline as early as month 12,3

66% mean reduction from baseline in tearing scores at month 42,3

Image
See reductions in tearing scores vs baseline over 4 months
Image
See reductions in tearing scores vs baseline over 4 months

Least squares mean difference based on linear mixed model for repeated measures with treatment, visit, proportion of time within VKC season, baseline, treatment by visit, and patient as covariates.
Each symptom score at each visit was measured using a Visual Analogue Scale (0=no experience of symptom to 100=maximal experience of symptom).

Image
Verkazia effectively treats tearing

Reductions in mucous discharge scores from baseline as early as month 12,3

67% mean reduction from baseline in mucous discharge scores at month 42,3

Image
See reductions in mucous discharge scores vs baseline over 4 months
Image
See reductions in mucous discharge scores vs baseline over 4 months

Least squares mean difference based on linear mixed model for repeated measures with treatment, visit, proportion of time within VKC season, baseline, treatment by visit, and patient as covariates.
Each symptom score at each visit was measured using a Visual Analogue Scale (0=no experience of symptom to 100=maximal experience of symptom).

Image
Verkazia effectively treats mucous discharge